Drug intelligence / Profile preview

hydroxychloroquine + prednisone

Development stage
Phase 4
Lead developer
Sanofi
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Hydroxychloroquine + prednisone is a combination therapy involving two distinct pharmaceutical agents commonly used in the management of autoimmune and inflammatory diseases, such as rheumatoid arthritis and systemic lupus erythematosus. Hydroxychloroquine is an antimalarial agent that also acts as a disease-modifying anti-rheumatic drug (DMARD), primarily by antagonizing toll-like receptors 7 and 9, thereby modulating immune system activity and reducing inflammation. Prednisone is a synthetic glucocorticoid corticosteroid that exerts potent anti-inflammatory and immunosuppressive effects by binding to the glucocorticoid receptor, influencing gene expression to suppress pro-inflammatory cytokines. This combination may be prescribed together to achieve better control of disease activity while potentially allowing for lower doses of corticosteroids, thus minimizing steroid-related side effects[2][3][7]. Both drugs are small molecules taken orally.

Other names
Hydroxychloroquine + low-dose prednisoneHydroxychloroquine and low-dose prednisoneHCQ + prednisone
02

Targets

GR (Glucocorticoid receptor)TLR7 (Toll-like receptor 7)TLR9 (Toll-like receptor 9)

Beyond the preview

Go deeper on hydroxychloroquine + prednisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hydroxychloroquine + prednisone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call